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Abstract: Osteolytic bone disease is the major complication associated with the progression of multiple
myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated
bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs).
Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle
content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs,
highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in
EVs from bone marrow (BM) plasma of patients affected by smoldering myeloma (SMM) and MM.
Notably, we found that miR-129-5p, which targets different osteoblast (OBs) differentiation markers,
is enriched in MM-EVs compared to SMM-EVs, thus suggesting a selective packaging correlated
with pathological grade. We found that miR-129-5p can be transported to hMSCs by MM-EVs and,
by the use of miRNA mimics, we investigated its role in recipient cells. Our data demonstrated that
the increase of miR-129-5p levels in hMSCs under osteoblastic differentiation stimuli inhibited the
expression of the transcription factor Sp1, previously described as a positive modulator of osteoblastic
differentiation, and of its target the Alkaline phosphatase (ALPL), thus identifying miR-129-5p among
the players of vesicle-mediated bone disease.
Keywords: extracellular vesicles (EVs); exosomes; multiple myeloma (MM); bone disease; microRNAs;
osteogenic differentiation; transcription factor sp1
1. Introduction
Multiple myeloma (MM) represents the second most prevalent hematologic malignancy [1],
is classified in a heterogeneous group of diseases, plasma cellular dyscrasias, characterized by the
monoclonal expansion of bone marrow (BM) plasma cells that release a monoclonal immunoglobulin,
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called M component or paraprotein. The occurrence of MM is consistently preceded by two precursor
states: a pre-cancerous condition called gammopathy of undetermined significance (MGUS) and the
asymptomatic clonal plasma cell disorder called smoldering myeloma (SMM). SMM is distinguished
from MGUS by a much higher risk of progression to MM [2].
The major complication, associated with MM disease progression, which is not observed in the
other two conditions, is the bone disease. In fact, around 80% of patients develop osteolytic bone lesions
that lead to fractures and bone pain [3]. The occurrence of osteolytic bone disease is the consequence
of the alteration of the physiological balance between the activity of bone-resorbing osteoclasts (OCs)
and bone-forming osteoblasts (OBs) that results in the concomitant activation of osteoclastogenesis
and inhibition of osteoblastogenesis [4,5]. A better understanding of the underlying causes of bone
disruption in patients affected by MM is needed to develop new targeted therapeutic strategies aimed
at inhibiting osteolysis and stimulating OB differentiation. It has been extensively reported that MM
cells are able to induce the remodeling of the bone marrow stromal tissue to promote their growth and
survival. For this purpose, the bidirectional crosstalk between MM cells and Bone marrow stromal
cells (BMSCs) is crucial [6].BMSC differentiation is regulated by a number of cytokines as well as
miRNAs [7,8]. To note, several miRNAs can exhibit inhibitory roles in osteogenesis by directly or
indirectly targeting key osteogenic factors [9]. In order to further investigate the multiple mechanisms
adopted by MM cells to influence the tumor microenvironment, in the last years, we and other research
groups have been working on understanding if MM-extracellular vesicles(EVs) can affect the balance
between OC and OB functions.
EVs are a heterogeneous population of membrane-bound vesicles, released by almost all cell types,
differing in sizes, secretory pathways, and content [10,11]. EVs have a sophisticated composition, including
lipids, proteins, DNA, coding and non-coding RNA species, and, through different mechanisms, can
interact with target cells, leading to phenotypic changes of recipient cells. For all these reasons, they are
considered mediators of intercellular communication also in the tumor microenvironment. Numerous
observations indicate that EVs play a crucial role in MM pathogenesis [12,13] by affecting endothelial cell
functions [14–17], enhancing tumor cell proliferation [18], and promoting immunosuppression [14,19].
In addition, EVs that contain miRNAs may be an important means of cell–cell communication within
the MM tumor microenvironment [20]. Recent studies have shown that MM cell-derived EVs play
a relevant functional role in activating osteoclast differentiation [21–23] and that the presence of the
EGFR ligand amphiregulin is partially responsible for OC activation [21]. Interestingly, increasing
evidence reported that MM EVs are also effective in inhibiting osteogenesis, in particular by blocking
the osteoblastic differentiation of mesenchymal cells [21,23–27]. In particular, the decrease in ALPL
levels, both at the transcript and protein levels, was largely correlated with MM-EVs mediated osteogenic
inhibition [21,23,24]. We have previously demonstrated that MM1.S-derived EVs led to a reduced
expression of OB differentiation markers (ALPL, OCN, Col1A1) in hTERT-MSCs under osteogenic
conditions [21]. Further observation showed that EVs from the syngenic murine model of MM blocked
OBs differentiation and their functionality in vitro [23]. In particular, the authors found that EVs contain
and transfer the inhibitor of Wnt/β-catenin pathway, Dickkopf-1 (DKK1) [28], to OBs, leading to the
reduction of the OB marker Runx2, Osterix, and Collagen 1A1 [23]. The EV-mediated decrease of Runx2
expression in hMSCs was also correlated to the transport of exosomal antisense lncRUNX2 from MM cells
to recipient hMSCs [27].
Specificity Protein 1 (Sp1) is a key transcription factor involved in several biological pathways,
acting as positive or negative gene expression regulator; in particular it plays a critical role in cell
proliferation, cell cycle progression and apoptosis [29–31]. Emerging studies report a role of Sp1
in OB differentiation; in fact, its downregulation prevents vascular calcification by inhibiting the
transdifferentiation of vascular smooth muscle cells into OBs [32]. In addition, Sp1 increases the
mineralization of osteoblastic cells [33]. Modulation of Sp1 by EVs was recently correlated to their
content; in particular Wang and colleagues reported that TGF-β1 increases miR-135 levels in MSC-EVs.
EVs containing miR-135 were able to promote chondrocyte proliferation by down-regulating Sp1 [34].
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Although different mediators of the inhibitory effect of MM EVs have been already identified,
the rich and heterogeneous content of EVs deserves further investigation in order to deeply investigate
how MM cell-derivedEVs may act on osteoblast differentiation. In particular, this study aims to
correlate the EV-mediated osteogenic inhibition of hMSCs with vesicle content, focusing on miRNAs.
2. Results
2.1. MM EVs Are Internalized by hMSCs and Inhibit Their Osteogenic Differentiation
EVs released by MM cells have been recently correlated to the MM bone disease by directly
activating osteoclast functions and, at the same time, by inhibiting the osteogenic differentiation of
hMSCs [21–25,27]. In our previous study, we demonstrated that MM EVs inhibit the osteoblastic
differentiation of hTERT-MSCs [21]; here we tried to shed light on the mechanism underlying these
effects. We first confirmed that EVs from MM1.S and RPMI 8226 cells were internalized by hMSCs
(Figure 1A). Then, in order to investigate the effects induced by EVs in hMSCs during osteogenic
differentiation, we analyzed the mRNA levels of the early osteogenic differentiation markers, i.e., Osterix,
ALPL, Col1A1, and Osteocalcin (OCN), in hMSCs treated for 10 days with EVs from MM cell lines. As
reported in Figure 1B, we found a significant and similar reduction of the early markers Osterix, ALPL
and Col1A1, between EVs released from the two cell lines, a variable diminished level of Osteocalcin,
but we didn’t observe any change in the expression level of Osteopontin, a late osteogenic marker
(data not shown). Taken together these results confirmed the role of MM-EVs in inhibiting the early
commitment of hMSCs toward osteogenic differentiation.
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Figure 1. (A) Cellular internalization of MM1.S and RPMI 8226-derived EVs into hMSCs was analyzed by
confocal microscopy. HMSCs were incubated for 4 h with MM-EVs labeled with PKH26 (red). HMSCs were
stained with ActinGreen (green), nuclear counterstaining was performed using Hoescht (blue). Samples
were analyzed at the confocal microscope (scale bar = 20µm). (B) The Real-Time PCR analyses of Osterix,
ALPL, Col1A1 and OCN were performed on hMSCs maintained in the osteogenic medium after 10 days
of treatment with MM1.S and RMPI 8226-derived EVs. Data were normalized for β-actin and values are
expressed as Fold Change in gene expression that occurred in cells treated with EVs versus untreated hMSCs
(dotted line). The statistical significance of the differences was analyzed using a two-tailed Student’s t-test.
2.2. MM-EVs Contain miRNAs Involved in hMSCsOsteogenic Inhibition
To investigate a possible correlation between the EV-mediated osteogenic inhibition of hMSCs
and the miRNA vesicle content, we determined the miRNA expression profile of MM1.S EVs,
using a quantitative TaqMan real-time PCR-based microRNA array card. Among the 384 microRNAs
contained in the card, we identified 164 miRNAs in EVs from the MM1.S cell line and we
then selected the most enriched ones based on their expression level (Ct <31, 2ˆ∆Ct ≥0.002).
Out of forty enriched miRNAs, seven of them have been previously correlated with osteogenesis
regulation (hsa-miR-34a [35–37], hsa-miR-30c [26,38], hsa-miR-127-5p [39,40], hsa-miR-106a [41],
hsa-miR-188-3p [37], hsa-miR-129-5p [42–45], hsa-miR-146a [46,47] (Figure 2)).
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Figure 2. Heat map diagram of the miRNA profile of MM1.S-EVs based on miRNA expression (2ˆ∆Ct
vs snoU6). The dotted line separates the miRNAs with higher abundance (Ct <31, 2ˆ∆Ct ≥0.002) from
the less abundant species (Ct >31, 2ˆ∆Ct <0.002).
Among those, we decided to focus our attention on hsa-miR-30c, hsa-miR-127-5p, hsa-miR-129-5p,
and hsa-miR-146a since their validated and predicted targets are osteoblast differentiation markers.
The presence of the four selected miRNAs in MM EVs was further confirmed by qRT-PCR in MM1.S and
RPMI 8226 EVs as well as in the respective producing cell lines (Figure 3A). Although each of the four
miRNAs is expressed in the two cell lines and is contained in their respective vesicles, we compared
the abundance of each miRNA among the two MM cell lines and among the two EV population; to
note we observed a comparable amount of miR-30c, miR-127-5p, and miR-129-5p in the two cell lines,
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while miR146a-5p is more abundant in MM1.S cells compared with RPMI8226. We performed the
same analysis on EVs and we found that miR-30c is more abundant in RPMI8226-EVs compared with
MM1.S-EVs, while the levels of the other miRNAs was comparable among the two vesicle types.
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Figure 3. (A) Real-time PCR analyses for miR-30c, miR-127-5p, miR-129-5p and miR-146a-5p was
performed on MM1.S and RPMI 8226 cells and EVs. The statistical significance of the differences was
analyzed using a two-tailed Student’s t-test. (B) Real-time PCR analysis for miR-30c, miR-127-5p,
miR-129-5p and miR-146a-5p was performed on cells and EVs from the bone marrow aspirates of
MM patients (n = 6to7) and SMM patients (n = 4to5). Values are plotted as 2ˆ∆Ct versus snoU6.
The statistical significance of the differences was analyzed using Mann-Whitney test.
Once we identified and selected specific microRNAs, we evaluated and compared their abundance
in EVs and cells from the bone marrow aspirate samples of patients at different stages of the disease
(MM and SMM). As shown in Figure 3B, we did not observe differences in the level of these miRNAs
in cells from the two clinical conditions (upper panel), while we interestingly observed a significant
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enrichment of miR-129-5p in MM EVs compared to SMM (lower panel). Interestingly, two patients
with extensive bone disease release EVs with higher miR-129-5p levels. Overall this result may suggest
a selective packaging of miR-129-5p into MM-EVs correlated with pathological grade. The clinical
characteristics of patients enrolled in this study are summarized in Supplementary Table S1.
2.3. MiR-129-5p Level Increases in hMSCs afterEV Incubation
Considering that, unlike MM, SMM patients do not exhibit lytic bone lesions, in order to identify
the miRNAs that could affect bone differentiation, we focused our study on the miRNAs enriched in EV
from MM patients. We first assessed the expression levels of these miRNAs in hMSCs after 6 and 24h of
treatment with MM patient EVs (n = 4). To note, three out four EV samples were isolated from patients
with extensive bone disease. Interestingly, we found a time-dependent increase of miR-129-5p levels
and an increase of miR-146a-5p at 24h (Figure 4A). MiR-146a-5p was previously found in MM EVs and
its level increased in MSC after EV treatment. Further, the authors found that the increased level of
this miRNA in MSCs led to MM cell growth and migration [48]. Considering the significant increased
levels of miR-129-5p among MM EVs (Figure 3B, lower panel) and the increased amount of the miRNA
in hMSCs after EV incubation, we decided to focus on miR-129-5p. To correlate the increased level of
the miRNA in target cells with its delivery by EVs, we analyzed the miRNA precursor level. As shown
in Figure 4B, we didn’t observe any difference in the expression of the pri-miR-129, thus suggesting an
EV-mediated transport of the miRNA from MM cells to hMSCs rather than an EV-mediated induction.
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Figure 4. (A) Real-time PCR analyses for miR-30c, miR-127-5p, miR-129-5p and miR-146a-5p were
performed on hMSCs incubated for 6 (left panel) and 24h (right panel) with EVs from the bone marrow
plasma of MM patients (n = 4). Data were normalized for snoU6. Values are expressed as Fold Change
in miRNA expression that occurred in cells treated with EVs versus untreated hMSCs (dotted line).
(B) The Real-Time PCR analyses of pri-miR-129 were performed on hMSCs incubated for 6 and 24h
with EVs from the bone marrow plasma of MM patients (n = 3). Data were normalized for β-actin
and values are expressed as Fold Change in the pri-miRNA expression that occurred in cells treated
with EVs versus untreated hMSCs. The statistical significance of the differences was analyzed using a
two-tailed Student’s t-test.
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2.4. MiR-129-5p Inhibits ALPL Expression in hMSCs
Three publicly available bioinformatics databases (TargetScan, microRNA.org, and miRWalk)
were used to analyze genes targeted by miR-129-5p (Figure 5A, upper panel). Among the miRNA
predicted targets, we found ALPL (Figure 5A, lower panel), an early marker of hMSCsosteogenic
differentiation, whose down-regulation was largely associated with MM EVs-mediated osteogenic
inhibition [21,23,24]. To investigate a possible role of miR-129-5p on the EV-mediated osteogenic
inhibition of hMSCs, and in particular, on ALPL expression, we transfected hMSCs with the miRNA
mimic (Supplementary Figure S1) and subsequently analyzed ALPL levels. We found a reduction of
the expression of ALPL both at the mRNA (Figure 5B) and the protein level (Figure 5C).
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Figure 5. (A, upper panel) The target genes of hsa-miR-129-5p were predicted using three different
bioinformatics databases (Target scan, miRWalk and microRNA.org). TheVenn diagram was generated
using the FunRich tool available online. (A, lower panel) The sequence alignment between miR-129-5p
and the 3′-UTR of ALPL mRNA predicted by TargetScan. (B) The Real-time PCR analysis of ALPL
in hMSCs transfected for 24, 48 and 72h with miR-129-5p mimic. Data were normalized for β-actin.
Values are expressed as Fold Change in gene expression that occurred in cells transfected with
miR-129-5p mimic versus hMSCs transfected with mimic negative ctrl for each time point (dotted
line). The statistical significance of the differences was analyzed using a two-tailed Student’s t-test.
(C) ALPL release was quantified by ELISA in the supernatant of hMSCs transfected for 24 and 72h with
miR-129-5p mimic and with mimic negative ctrl. Values are reported as ALPL concentration in ng/mL.
The statistical significance of the differences was analyzed using a two-tailed Student’s t-test.
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2.5. MiR-129-5p and MM EVs Inhibit the Transcription Factor SP1 Expression in hMSCs
Starting from this data, we next investigated the other targets of miR 129-5p by using the
publicly available bioinformatics tool miRTargetLink Human (https://ccb-web.cs.uni-saarland.de/
mirtargetlink/) [49]. In Figure 6A, the central node represents miR-129-5p, surrounded by the validated
targets with strong (e.g., luciferase assay in green) and weak (e.g., microarray in blue) evidence
and the predicted targets in yellow. Among the validated target with strong evidence (Figure 6A,
right panel), we found the transcription factor Sp1, largely described as a positive modulator of
OB differentiation [33,50–52]; it cooperates with Osterix [51,53], and is a transcriptional enhancer of
ALPL. Several studies have reported that Sp1 expression is downregulated in cells overexpressing
miR-129-5p [54,55]. Therefore, we evaluated Sp1 expression in hMSCs transfected with miR-129-5p
mimic and we found that, also in hMSCs, Sp1 is downregulated by miR-129-5p overexpression
(Figure 6B). According to this evidence, and to the described role of Sp1 as a positive modulator of
osteogenic differentiation of hMSCs, we evaluated the transcription factor levels in hMSCs treated
with EVs from MM patients. We observed that Sp1 expression is reduced in target cells treated for 10
days with EVs, both at mRNA (Figure 6C) and protein (Figure 6D) level. Overall, these data indicated
in Sp1 modulation a new mechanism by which MM EVs may inhibit hMSCs osteogenic differentiation.
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Figure 6. (A) The target and predicted genes of hsa-miR-129-5p were analyzed by the bioinformatics
tool miRTargetLink Human. The central node represents miR-129-5p, surrounded by the validated target
with strong (green) and weak (blue) evidence and the predicted targets in yellow. (B) The Real-time PCR
analysis of Sp1 in hMSCs transfected for 24, 48 and 72h with miR-129-5p mimic. Data were normalized
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for β-actin. Values are expressed as Fold Change in gene expression that occurred in cells transfected
with miR-129-5p mimic versushMSCs transfected with mimic negative ctrl for each time point (dotted
line). The statistical significance of the differences was analyzed using a two-tailed Student’s t-test.
(C) The Real-time PCR analysis of Sp1 was performed on hMSCs maintained in the osteogenic medium
after 10 days of treatment with MM1.S and RMPI 8226-derived EVs. Data were normalized for β-actin
and values are expressed as Fold Change in gene expression that occurred in cells treated with EVs
versus untreated hMSCs (dotted line). The statistical significance of the differences was analyzed using
a two-tailed Student’s t-test. (D) The expression of SP1 was evaluated by western blotting in hMSCs
treated for 10 days with MM1.S and RPMI 8226-derive EVs.
Interestingly, a bioinformatics analysis, focusing this time on the transcription factor Sp1 (central
node in Figure 7, left panel), revealed that among the miRNAs that target Sp1 with strong evidence,
the 50% were identified by us in MM1.S EVs by TaqMan real-time PCR-based miRNA array card
(Figure 7, right panel, red circle). Altogether these data suggest that several mediators of the osteogenic
differentiation of hMSCs are modulated by MM EVs and that, together with miR-129-5p, other miRNAs,
delivered by EVs may cooperate to decrease the osteogenic potential of hMSCs.
Figure 7. The miRNAs that target Sp1 were analyzed by the bioinformatics tool miRTargetLink Human.
The central node represents Sp1, surrounded by the miRNAs that target Sp1 with strong (green)
and weak (blue) evidence. Red circles indicated miRNAs that target Sp1 and that were identified
in MM1.S-EVs.
3. Discussions
Multiple lines of evidence define the involvement of EVs in MM progression as they can act
on several cellular targets and at different levels of disease progression [12–19]. In particular, recent
findings have highlighted the role of EVs as inducers of MM-osteolytic bone disease [21–27].
Although some of the mediators of this effect have been identified, a further description of the
content of the EVs and the identification of additional molecules responsible for the EV-mediated
activation of OCs and the inhibition of OBs would be useful to develop new diagnostic and prognostic
markers in MM management. In the current study, we assess if miRNAs transported by EVs may have
a role in the inhibition of osteoblast differentiation.
OBs are derived from bone marrow MSCinduced to differentiate bymicro-environmental cues
represented by cytokines and extracellular matrix components [56]. In MM patients, the osteogenic
ability of mesenchymal progenitors to differentiate to mature OBs is disrupted [57–59], as evidenced
by the decrease in the levels of Osterix, the major osteoblast transcriptional activator, and of the bone
formation markers, i.e., ALPL and Collagen type I α1 chain [60–62]. In this context, we found that
MM-EVs strongly downregulate the expression of these three markers actively participating in the
inhibition of the first differentiation steps of mesenchymal cells.
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It is already well known that EVs contain several species of non-coding RNAs including miRNAs
that can be carried and transferred to target cells, thus affecting their phenotype [63]. Here, we found
that many of the miRNAs identified in MM EVs have been previouslycorrelated to the inhibition
of osteogenic differentiation markers and that the levels of the miR-129-5p are correlated with the
pathological grade of MM. Of note, miR-129-5p contains the hEXO motif, a short sequence previously
identified by Santangelo et al. which is recognized by the RNA-Binding Protein SYNCRIP, leading to
the exosomal enrichment of some miRNAs [64]. This observation enforces the hypothesis of a selective
packaging for miR-129-5p.
A very interesting aspect emerging from the analysis on patient samples is that, since the
occurrence of MM is often preceded by the asymptomatic plasma cell proliferative disorder (SMM) [65],
vesicle-associated miR-129-5p may represent a new biomarker for the risk stratification; further studies,
as well as the increase in the number of enrolled patients, are needed to validate this point.
Concomitantly, by mimic transfection, we investigated the effect of miR-129-5p on hMSCs by
focusing on the predicted and validated osteogenic markers. MiR-129-5p was found to bind to the
3′UTR of COL1A1 mRNA in gastric cancer [42,44] and hepatic stellate cells [43]. Consistent with these
findings, we observed a downregulation of COL1A1 mRNA in hMSCs transfected with miR129-5p
mimics (data not shown). The decrease in ALPL, induced by EVs, and specifically by miR-129-5p,
supports the role of EV-miRNAs in MM bone disease.In fact, alkaline phosphatase is decreased in the
serum of patients with MM bone involvement [66], while an increase in its level, in patients treated
with bortezomib, was associated with treatment response [67].
Once in hMSCs, miR-129-5p can affect cell phenotype by targeting different transcripts;
bioinformatics analyses revealed that several validated targets of miR-129-5p are involved in bone
remodeling pathways, such as the ATP-binding cassette transporters [68,69] and Notch1 [70,71].
Of note, among the validated targets, we found the transcription factor Sp1 [54,55]. Sp1 was previously
described as a positive regulator of OB differentiation [33,50–52], in fact, its downregulation in a
human fetal osteoblastic cell line (hFOB) resulted in reduced expression of Frizzled-1 and a decrease in
ALP activity, while its overexpression increased osteosarcoma cell Saos2 mineralization [33]. Further,
Sp1enhances Runx2 promoter activity during osteogenesis progression [72].
Our study highlighted a novel mechanism by which MM EVs can inhibit osteoblast differentiation,
by reducing the expression of Sp1 in hMSCs. Interestingly, focusing on the validated miRNAs that target
Sp1, half of them are present in MM-EVs and are known to have a role in osteogenic differentiation of
MSC. For example, miR-21-5p inhibited the osteogenic differentiation in Periodontal Ligament Stem
Cells by targeting Smad5 [73]. In addition, its presence in osteosarcoma exosomes was correlated
with bone resorption activity of pre-osteoclast cells. The miR-27a-3p expression is upregulated in
osteosarcoma cell lines compared with normal human osteoblastic cells [74]. The evidence that different
molecular players, with the same target, are delivered by EVs, emphasizes the ability of EVs to strongly
affect the phenotype of recipient cells. Further investigation are needed to deeply investigate the
in vivo contribution of Sp1 in the osteogenic differentiation of MSC in patient affected by MM. At this
stage, consistent with previous data, we correlated the MM-EV miRNA content with the dimished
Sp1 levels in hMSC. To date, Sp1 expression was correlated to MM cell proliferation [75,76] but its
expression in hMSC during MM bone disease development still need to be explored.
In conclusion, our study provides new insights into the role of MM EVs in inhibiting the osteogenic
differentiation of hMSCs focusing initially on the content of EVs. Then, taking into consideration the
increase in miR-129 levels in hMSCs after EV treatment, we unveiled a novel mechanism, by which
MM EVs may act on osteoblast differentiation.
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4. Materials and Methods
4.1. Cell Cultures
MM cell lines, MM1.S and RPMI 8226 were purchased from ATCC (Manassas, VA, USA) and
cultured in RPMI 1640 medium (Euroclone, UK) supplemented with 10% fetal bovine serum (FBS,
Euroclone s.p.a., Milan, Italy). FBS was previously ultracentrifuged to deplete it from exosomes
(exosome- free FBS). Human Mesenchymal Stem Cells (hMSCs) were obtained from Lonza (Lonza,
Walkersville, MD, USA) and grown in Mesenchymal Stem Cell growth medium (MSCGM BulletKit™,
Lonza, Walkersville, MD, USA) to maintain them into an undifferentiated condition and in Mesenchymal
Stem Cell Osteogenic Differentiation Medium to induce osteogenic differentiation (MSC Osteogenic
Differentiation BulletKit™, Lonza). Cells were routinely tested for mycoplasma contamination using
N-Garde Kit For Mycoplasma Detection (Euroclone).
4.2. Purification of Primary Plasma Cells
Human primary plasma cells were isolated from the bone marrow aspirates of patients affected
by MM patients (n = 7) and by Smouldering Multiple Myeloma (SMM, n = 5) in accordance with the
Declaration of Helsinki guidelines and the Ethics committee of the Hospital of the University of Palermo
(date of approval 14/11/2018, report N◦10/2018). Bone marrow blood sampleswere diluted with PBS
and mononuclear cells were separated by Ficoll-Paque gradient centrifugation (GE Helthcare-Bio
Science, Uppsala, Sweden). The collected cells were pelleted and stored for further RNA isolation.
4.3. Extracellular Vesicle Isolation
Extracellular vesicles (EVs) were isolated from the conditioned culture medium of MM1.S and
RPMI 8226 after a 48h culture period in the presence of exosome- free FBS. EVs were collected by
differential centrifugation; conditioned culture medium was centrifuged subsequently for 5 min at
300× g, 15 min at 3000× g, and 30 min at 10,000× g and then ultracentrifuged for 105 min at 100,000×
g in a Type 70 Ti, fixed angle rotor. EVs were also isolated from the bone marrow (BM) plasma of
patients affected by MM (n = 7) and by SMM (n = 5). All patients provided written informed consent in
accordance with the Declaration of Helsinki. The Ethics Committee of the Hospital of the University of
Palermo (Italy) approved the study. EVs were isolated from human plasma and prepared as described
above. EV pellets were washed and suspended in PBS, and vesicle protein content was determined by
the Bradford assay.
4.4. Internalization of MM-Derived EVs by hMSCs
MM1.S and RPMI 8226 EVs were labeled with PKH26 Red Fluorescent Cell Linker Kits
(Sigma–Aldrich, USA) following the datasheet information. EVs, collected as previously described,
were incubated for 15 min at room temperature with PKH26 dye previously diluted in the diluent
C solution. Labeled EVs were washed in PBS; the pellets were suspended in the medium and
incubated with hMSCs, grown on coverslips, for 4 h. After incubation, hMSCs were fixed with PFA 4%,
permeabilized with 0.1%TritonX-100, stained with Actin Green (Molecular Probes, Life Technologies,
Carlsbad, CA, USA) that binds actin with high affinity. Nuclei were then stained with Hoechst
(Molecular Probes, Life Technologies, Carlsbad, CA, USA). Preparations were analyzed by confocal
microscopy (Nikon A1).
4.5. hMSCs Treatment with EVs
Cells were plated in 12-well plates in the basal Mesenchymal Stem Cell growth medium; 24 h
after seeding, when cells were 70% confluent, the media was replaced with the Mesenchymal Stem
Cell Osteogenic Differentiation Medium. Cells were treated for 10 days with EVs from MM1.S and
RPMI 8226 (50 µg/mL) to assess the effect of EVs on the osteogenic differentiation of hMSCs; the media
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were changed every 3 days. Cells were also treated for 6 and 24h with EVs from plasma samples to
further evaluate the miRNA expression levels.
4.6. MiRNA Expression Profiling
RNA was extracted from MM1.S EVs by using the IllustraRNAspin Mini Isolation
Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) according to the manufacturer’s
recommendations. 200 ng of total RNA was reverse transcribed using Megaplex™ RT Primers
Human Pool A (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.
The reaction was carried out at 16 ◦C for 2 min, 42 ◦C for 1 min, 50 ◦C for 1 s for 40 cycles, 85 ◦C for 5
min then hold at 4 ◦C.
To identify the miRNA profile of MM1.S EVs, real-time TaqMan PCR was carried out by using
the TaqMan microRNA array Human Pool A cards containing 384 different miRNAs (Thermo Fisher
Scientific, Waltham, MA, USA). The cDNA obtained in the previous step was diluted, mixed with
TaqMan Gene Expression Master Mix and loaded into each of the eight fill ports on the TaqMan®
Human MicroRNA Array A (Life Technologies, Carlsbad, CA, USA). The array was centrifuged twice
at 1200 rpm for 1 min and run on ABI-PRISM 7900 HT Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) using the manufacturer’s recommended program. Ct values for each miRNA
were normalized using thereferencesnoU6 RNA. Relative miRNA levels were expressed as 2ˆ∆Ct.
The HeatMap has been generated using Matlab 2019a software. Color scaling is set to log scale.
4.7. Cell Transfection
Transfection of miRNA mimic in hMSCs was performed using the Lipofectamin 3000 Transfection
Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. Cells were plated
in 12-well plates; 24 h after seeding, when cells were 70% confluent, cells were transfected with
30pmoles/mL of hsa-129-5p mimic (cat.number 4464066, Life Technologies), or scrambled negative
control (4464058, Life Technologies). Twenty-four, 48 and 72 h after transfection, the medium was
collected and the cells processed for RNA isolation.
4.8. RNA Isolation and Real-Time PCR
RNA was extracted using the commercially available IllustraRNAspin Mini Isolation Kit (GE
Healthcare, Little Chalfont, Buckinghamshire, UK), according to the manufacturer’s instructions.
RNA was isolated from cell lines, primary cells as well as EVs. Total RNA was reverse transcribed to
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). For quantitative Sybergreen real-time PCR, the reaction was carried out in a total volume of
20µLcontaining 2× SYBR Green I Master Mix (Applied Biosystems), 2µLcDNA, and 300 nM forward
and reverse primers. The oligonucleotides used were reported in the Table 1 below:
Table 1. Primer sequence used for gene expression analysis.
Gene Primer Forward Primer Reverse
B-Actin TCCCTTGCCATCCTAAAAAGCCACCC CTGGGCCATTCTTCCTTAGAGAGAAG
OSX TGCTTGAGGAGGAAGTTCAC AGGTCACTGCCCACAGAGTA
ALPL CCACGTCTTCACATTTGGTG AGACTGCGCCTGGTAGTTGT
COL1A1 TGTGGATGCCTCTTGGGTATC TTTTGGCCATCTCTTCCTTCA
OCN AGCAAAGGTGCAGCCTTTGT GCGCCTGGGTCTCTTCACT
SP1 GCCTCCAGACCATTAACCTCAGT GCTCCATGATCACCTGGGGCAT
For miRNA expression, 10 ng of RNA was reverse transcribed according to the manufacturer’s
instructions (TaqManMicroRNA Reverse Transcription, Applied Biosystem). Taqman probes, from
Applied Biosystems were used to analyze: miR-30c-5p, miR-127-5p, miR-129-5p, miR-146-5p, and U6.
Real-time PCR was performed in 48-well plates using the Step-One Real-Time PCR system (Applied
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Biosystems) in duplicated for each data point. Relative changes in the target mRNA content, relative to
a housekeeping gene (β-actin), and in the target miRNA content, relative to housekeeping U6, were
determined with the ∆∆ct Method.
4.9. ELISA ALPL
ALPL concentration in the conditioned medium of hMSCs was measured using the ALPL ELISA
Kit (MyBioSource), following the manufacturer’s protocol. The conditioned medium of hMSCs was
medium was collected after 24 or 72h of transfection with miR-129-5p mimic. Data were expressed as
ALPL concentration in ng/mL.
4.10. Western Blotting
Total proteins from hMSCs cells, treated for 10 days with MM-EVs, were isolated and analyzed by
SDS-PAGE followed by western blotting. Antibodies used in the experiments were as follows: anti-SP1
antibody (Abcam) and anti-GAPDH (Santa Cruz Biotechnology, CA, USA).
4.11. Bioinformatics Tools
TargetScan [77], miRWalk [78] and microRNA.org [79] bioinformatics databases were used to
analyze the predicted target mRNAs of the selected microRNAs. FunRich analysis tool [80] was used to
generate a Venn diagram of the relationships between the 3 datasets generated above. miRTargetLink
Human [49] was used to generate the miRNA-target interaction network.
4.12. Statistical Analysis
Data are reported as mean ± standard deviation (SD) of 3 or more biological replicates. Statistical
analysis was performed using GraphPad Prism software (GraphPad software, Inc, La Jolla, CA).
The statistical significance of the differences was analyzed using a two-tailed Student’s t-test.
When the data were not normally distributed, Mann-Whitney test was used. A p-value ≤0.05
was considered significant.
4.13. Ethical statement:
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki; the protocol was approved
by the Ethics Committee of the Hospital of the University of Palermo (date of approval 14/11/2018,
report N◦10/2018).
5. Conclusions
In summary, in this study, we have provided evidence of the role of miRNAs, delivered by
MMEVs, on the EV-mediated osteogenic inhibition of hMSCs. In particular, we found that MM-EVs
contain several miRNAs involved in osteogenic regulation. Among those, miR-129-5p is enriched
in MM EVs and is delivered in hMSCs, leading to the downregulation of ALPL and Sp1 (Graphical
abstract). Further, our study uncovered the transcription factor Sp1, already described as a positive
modulator of hMSCsosteogenic differentiation, as a novel target of MM EVs.
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